What is PromarkerEso and who developed it?

PromarkerEso is a blood test developed by Proteomics International for the early detection of esophageal adenocarcinoma.

How does the PromarkerEso blood test compare to current EAC diagnostics?

The PromarkerEso test is a simple, non-invasive blood test, offering an alternative to more invasive endoscopic procedures currently used for EAC detection.

Why is early detection of esophageal adenocarcinoma important?

Esophageal adenocarcinoma has very low survival rates, with many patients facing a poor prognosis if diagnosed at later stages.

Home / Health / New Blood Test Detects Deadly Throat Cancer Early

New Blood Test Detects Deadly Throat Cancer Early

16 Jan

•

Summary

Prometel International's PromarkerEso blood test gets patent.
Test aims to detect esophageal adenocarcinoma early.
EAC has low survival rates, with many diagnosed late.

New Blood Test Detects Deadly Throat Cancer Early

Proteomics International has achieved a significant milestone with the granting of a Canadian patent for its PromarkerEso blood test. This innovative diagnostic technology is designed to detect early signs of esophageal adenocarcinoma (EAC), an aggressive and often deadly form of throat cancer.

The PromarkerEso test represents a considerable advancement, offering a non-invasive method for early disease identification. Current diagnostic methods for EAC, a cancer frequently associated with chronic acid reflux, often involve more invasive endoscopic procedures. This new blood test promises to identify the disease at much earlier, more treatable stages.

Esophageal adenocarcinoma poses a significant global health threat, with survival rates falling dramatically when diagnosed late. In countries like the US, where GERD is prevalent, many cases are detected only in advanced stages, leading to grim prognoses and a limited lifespan for affected patients.